DOI QR코드

DOI QR Code

Impact of Tumor Length on Survival for Patients with Resected Esophageal Cancer

  • 발행 : 2014.01.30

초록

Background: Tumor length in patients with esophageal cancer (EC) has recently received great attention. However, its prognostic role for EC is controversial. The purpose of our study was to characterize the prognostic value of tumor length in EC patients and offer the optimum cut-off point of tumor length by reliable statistical methods. Materials and Methods: A retrospective analysis was conducted on 71 consecutive patients with EC who underwent surgery. ROC curve analysis was used to determine the optimal cut-off point for tumor length, measured with a handheld ruler after formalin fixation. Correlations between tumor length and other factors were surveyed, and overall survival (OS) rates were compared between the two groups. Potential prognostic factors were evaluated by univariate Kaplan-Meier survival analysis. A P value less than 0.05 was considered significant. Results: There were a total of 71 patients, with a male/female divide of 43/28 and a median age of 59. Characteristics were as follows: squamous/adenocarcinoma, 65/6; median tumor length, 4 (0.9-10); cut-off point for tumor length, 4cm. Univariate analysis prognostic factors were tumor length and modality of therapy. One, three and five year OS rates were 84, 43 and 43% for tumors with ${\leq}4cm$ length, whereas the rates were 75, 9 and 0% for tumors >4 cm. There was a significant association between tumor length and age, sex, weight loss, tumor site, histology, T and N scores, differentiation, stage, modality of therapy and longitudinal margin involvement. Conclusions: Future studies for modification of the EC staging system might consider tumor length too as it is an important prognostic factor. Further assessment with larger prospective datasets and practical methods (such as endoscopy) is needed to establish an optimal cut-off point for tumor length.

키워드

참고문헌

  1. Beahrs OH and Myers MH (1983). Manual for staging cancer. 2nd ed. American Joint Committee on Cancer. J.B. Lippincott Company, Philadelphia. Chapter 9, pp 61-6
  2. Chao IK, Tseng CK, Wen YW, et al (2013). Using Pretreatment Tumor Depth and Length to Select Esophageal Squamous Cell Carcinoma Patients for Nonoperative Treatment After Neoadjuvant Chemoradiotherapy. Ann Surg Oncol, 20, 3000-8. https://doi.org/10.1245/s10434-013-2962-1
  3. Davies L, Mason JD, Roberts SA, et al (2012). Prognostic significance of total disease length in esophageal cancer. Surg Endosc, 26, 2810-6. https://doi.org/10.1007/s00464-012-2250-3
  4. Edge SB, Compton CC (2010). The american joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 17, 1471-4 https://doi.org/10.1245/s10434-010-0985-4
  5. Feng JF, Huang Y, Zhao Q (2013). Tumor length in elderly patients with esophageal squamous cell carcinoma: Is it a prognostic factor? Ups J Med Sci, 118, 145-52 https://doi.org/10.3109/03009734.2013.792887
  6. Gaur P, Sepesi B, Hofstetter WL, et al (2011). Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer, 117, 63-9. https://doi.org/10.1002/cncr.25373
  7. Mirinezhad SK, Somi MH, Ghasemi Jangjoo A, et al (2012). Survival Rate and Prognostic Factors of esophageal cancer in East Azerbaijan Province, North-west of Iran. Asian Pac J Cancer Prev, 13, 3451-54. https://doi.org/10.7314/APJCP.2012.13.7.3451
  8. Sillah K, Williams LR, Laasch HU, et al (2010). Computed tomography overestimation of esophageal tumor length: Implications for radiotherapy planning. World J Gastrointest Oncol, 2, 197-204. https://doi.org/10.4251/wjgo.v2.i4.197
  9. Siu KF, Cheung HC, Wong J (1986). Shrinkage of the esophagus after resection for carcinoma. Ann Surg, 203, 173-6. https://doi.org/10.1097/00000658-198602000-00011
  10. Sobin LH, Hermanek P, Hutter RV(1988). TNM classification of malignant tumors: a comparison between the new (1987) and the old editions. Cancer, 61, 2310-4. https://doi.org/10.1002/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X
  11. Somi M H, Farhang S, Mirinezhad S K, et al (2008). Cancer in East Azerbaijan, Iran: Results of a Population-based Cancer Registry. Asian Pac J Cancer Prev, 9, 327-30.
  12. Song Z, Wang J, Lin B, Zhang Y, et al (2012). Analysis of the tumor length and other prognosis factors in pT1-2 nodenegative esophageal squamous cell carcinoma in a Chinese population. World J Surg Oncol, 10, 273-9. https://doi.org/10.1186/1477-7819-10-273
  13. Wang BY, Goan YG, Hsu PK, et al (2011). Tumor length as a prognostic factor in esophageal squamous cell carcinoma. Ann Thorac Surg, 91, 887-93. https://doi.org/10.1016/j.athoracsur.2010.11.011

피인용 문헌

  1. Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5493
  2. Retrospective Study of Adjuvant Chemotherapy Effects on Survival Rate after Three-Field Lymph Node Dissection for Stage IIA Esophageal Cancer vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5169
  3. Prognostic factors in patients after definitive chemoradiation using involved-field radiotherapy for esophageal cancer in a phase II study vol.7, pp.5, 2016, https://doi.org/10.1111/1759-7714.12369
  4. Prognostic significance of tumor length in patients receiving esophagectomy for esophageal cancer pp.00224790, 2017, https://doi.org/10.1002/jso.24789
  5. FOXM1: A potential indicator to predict lymphatic metastatic recurrence in stage IIA esophageal squamous cell carcinoma vol.9, pp.8, 2018, https://doi.org/10.1111/1759-7714.12776